PRESS-RELEASE ·Filed May 4, 2026
Press release · FDA
Actionable Insight • Neutral
Monitor the initiation of patient enrollment and any subsequent clinical data readouts. The small market cap ($8M) could lead to volatility on enrollment updates.
Final — all horizons settled through T+60d ⚠ clustered
FBLG ▼ -52.57% at T+60d
NEUTRAL call -52.57% · α vs SPY -54.42% · entry $1.38 → $0.6546
T+1d
-3.62%
call -3.62% · α -4.42%
$1.33
settled 6mo ago
T+5d
-28.26%
call -28.26% · α -31.20%
$0.9900
settled 6mo ago
T+20d
-18.84%
call -18.84% · α -24.49%
$1.12
settled 5mo ago
T+60d
-52.57%
call -52.57% · α -54.42%
$0.6546
settled 3mo ago
Price Chart
Loading chart...
Executive Summary
FibroBiologics announced the release of the first cGMP batch of its CYWC628 drug product for a Phase 1/2 clinical trial in diabetic foot ulcers. This milestone enables patient enrollment but does not provide clinical data or financial impact.
Key Facts
- First cGMP batch of CYWC628 released for Phase 1/2 DFU trial
- Drug product passed all safety and quality testing
- Patient enrollment to begin
Financial Impact
No financial figures provided in the release
Risk Factors
- Clinical trial failure or delays
- Need for additional capital to fund trials
- Regulatory and manufacturing risks
Market Snapshot
Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
78% bullish (9 analysts)
Investment Themes
Biotech & Drug Discovery
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3286693 |
22 reports for FBLG
100% Hit rate @ T+5 Went positive at some point 6 of 8 best @ T+20▲ +33.83%
Filters
Rows
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 6d ago | EFFECT | $0.9199 | awaiting T+5 | — | $0.9221 (−0.24%) |
Oct 20, 2026 6d ago | EFFECT | $0.9199 | awaiting T+5 | — | $0.9221 (−0.24%) |
Oct 8, 2026 17d ago | 8-K | $1.13 $0.9710 | ▲ +14.07% | ▲ +12.10% | $0.9221 (+18.40%) |
Sep 15, 2026 5w ago | 8-K | $1.44 $1.43 | ▼ −0.69% | ▼ −1.51% | $0.9221 (−35.97%) |
Aug 24, 2026 9w ago | 8-K | $1.35 $1.72 | ▲ +27.41% | ▲ +26.94% | $0.9221 (−31.70%) |
Jul 31, 2026 12w ago | Press Release | $0.7910 $0.9800 | ▲ +23.89% | ▲ +21.87% | $0.9221 (+16.57%) |
Jul 17, 2026 14w ago | EFFECT | $0.8349 $0.7355 | ▲ +11.91% | ▲ +11.22% | $0.9221 (−10.44%) |
Jul 9, 2026 15w ago | 8-K | $0.8610 $0.8398 | ▼ −2.46% | ▼ −2.33% | $0.9221 (+7.10%) |
Jun 29, 2026 16w ago | 8-K | $0.9477 $0.8687 | ▲ +8.34% | ▲ +8.94% | $0.9221 (+2.70%) |
May 11, 2026 24w ago | Press Release | $0.9900 $1.09 | ▲ +10.10% | ▲ +10.19% | $0.9221 (−6.86%) |
Showing 10 of 22
US Market Status
Market Open — Closes in 5h 17m
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers